Immunex has presented the results of its first clinical trial of itsrecombinant Flt3 ligand, showing that the cytokine safely increases immune cells and may improve patients' defenses against cancer and infections.
The data, from a Phase I/II study involving 20 healthy volunteers, show that escalating doses of Flt3 ligand increased the levels of stem cells and dendritic cells. Daily injections of between 10 and 100mcg of the drug over 14 days resulted in up to 30-fold increases in dendritic cells and CD34 cells in the peripheral blood compared to placebo. The drug was well-tolerated and there was no evidence of mast cell stimulation, which could lead to allergic reactions.
Immunex is now planning to test Flt3 ligand in combination with other cytokines with the aim of reducing the number of blood collections required for stem cell transplants. The company has also initiated studies in patients with cancer. An article in the June issue of Nature Medicine has shown that Flt3 ligand can induce tumor regression in mice.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze